72 employees
Prelude Therapeutics is a developer of novel therapies intended to target key drivers of cancer cell growth, survival and resistance.
2016
$60M
from 2 investors over 2 rounds
Prelude Therapeutics Incorporated raised $50M on August 24, 2020
Investors: OrbiMed Advisors
Prelude Therapeutics Incorporated raised $60M on June 12, 2019